FDA Tightens Rules to Block Infections in Donated Tissues
Published Date: 2/3/2025
Notice
Summary
This update helps hospitals and tissue banks keep human cells and tissues safer by reducing the risk of spreading infections like sepsis and tuberculosis. The FDA is changing the deadline for when these safety steps should be put into action, giving everyone a clearer timeline to protect patients. These changes aim to keep people safe without causing big costs or delays.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Safer HCT/Ps: Sepsis Implementation Timeline
The FDA revised its guidance on human cells, tissues, and cellular and tissue-based products (HCT/Ps) to change the time by which it recommends hospitals and tissue banks put in place steps to reduce the risk of sepsis. You (as a patient) should see safer handling of HCT/Ps aimed at protecting patients, and the FDA says it intends these changes to avoid big costs or delays for providers.
Safer HCT/Ps: TB Implementation Timeline
The FDA revised its guidance on human cells, tissues, and cellular and tissue-based products (HCT/Ps) to change the time by which it recommends implementation of steps to reduce the risk of transmitting Mycobacterium tuberculosis (Mtb). This aims to make HCT/Ps safer for patients while seeking to avoid large costs or delays for hospitals and tissue banks.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in